(Q41091405)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26614429%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Nuclear PARP1 expression and its prognostic significance in breast cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26614429%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26614429%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Simona De Summa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26614429%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Anita Mangia

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26614429%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Giulia Partipilo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26614429%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Francesco Giotta

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26614429%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Giovanni Simone

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26614429%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

27 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26614429%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26614429%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26614429%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26614429%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

6143-6153

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26614429%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s13277-015-4465-0

1 March 2020

exact match

0 references

cites work

Global estimates of cancer prevalence for 27 sites in the adult population in 2008.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Declining death rates reflect progress against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Poly(ADP-ribose): novel functions for an old molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

The relationship between the roles of BRCA genes in DNA repair and cancer predisposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Novel agents and future directions for refractory breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

An update on PARP inhibitors--moving to the adjuvant setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Exploiting the homologous recombination DNA repair network for targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Biological and clinical significance of PARP1 protein expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Poly(ADP-ribose) polymerase 1 is a key regulator of estrogen receptor α-dependent gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

BRCAness profile of sporadic ovarian cancer predicts disease recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4465-0

Iniparib in metastatic triple-negative breast cancer

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

High Nuclear Poly(Adenosine Diphosphate-Ribose) Polymerase Expression Is Predictive forBRCA1- andBRCA2-Deficient Breast Cancer

1 reference

12 December 2020

Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node‑negative early breast cancer: 15-year follow-up.

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer

1 reference

12 December 2020

Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients.

1 reference

12 December 2020

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

1 reference

12 December 2020